发明名称 Heterocyclic CRF receptor antagonists
摘要 There is provided a CRF receptor antagonist comprising a compound of the formula (I) : A-W-Ar wherein, A is a group represented by the formula (A2), wherein ring Ab is a 5- or 6- membered ring which may be further substituted in addition to R1; ring Ac is a 5- or 6- membered ring which may be substituted; R1 is an optionally substituted hydrocarbyl, a substituted amino, an optionally substituted cyclic amino, a substituted hydroxy, a substituted sulfanyl, an optionally substituted sulfinyl, or an optionally substituted sulfonyl; X is carbonyl, -O-, -S-, -SO-, or -SO2-; Y1, Y2 and Q are independently optionally substituted carbon or nitrogen; ... is a single or double bond; W is a bond, an optionally substituted methylene, an optionally substituted ethylene, an optionally substituted imino, -O-, -S-, -SO-, or -SO2-; Ar is an optionally substituted aryl or an optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.
申请公布号 EP2522670(A1) 申请公布日期 2012.11.14
申请号 EP20120157517 申请日期 2005.04.06
申请人 TAKEDA PHARMACEUTICAL COMPANY LIMITED 发明人 GYORKOS, ALBERT CHARLES;BOYD, S. A.;CORRETTE, C. P.;CHO, S. Y.;TURNER, T. M.;ASO, K.;KORI, M.;MOCHIZUKI, M.;CONDROSKI, K. R.;SIEDEM, C. S.
分类号 C07D487/04;A61K31/407;A61K31/4704;A61K31/505;A61K31/517;A61K31/519;A61K31/52;A61K31/5383;A61P25/24;C07C225/20;C07D213/74;C07D215/233;C07D215/56;C07D221/02;C07D231/56;C07D237/28;C07D239/22;C07D239/46;C07D239/47;C07D239/56;C07D239/94;C07D239/95;C07D239/96;C07D265/34;C07D265/36;C07D455/02;C07D471/04 主分类号 C07D487/04
代理机构 代理人
主权项
地址